|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 694.00 EGP | -0.86% |
|
+5.40% | +98.74% |
| 06-10 | MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 05-05 | Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million | RE |
| Market Cap | 8.18B 164M 143M 132M 124M 232M 15.45B 234M 1.57B 608M 7.61B 615M 602M 26.41B | P/E 2024 |
14x | P/E 2025 | 584x |
|---|---|---|---|---|---|
| Enterprise Value | 9.29B 186M 162M 150M 141M 264M 17.55B 265M 1.78B 691M 8.64B 698M 683M 30B | EV / Sales 2024 |
0.78x | EV / Sales 2025 | 0.81x |
| Free-Float |
14.74% | Yield 2024 |
1.54% | Yield 2025 | - |
| 1 day | -0.86% | ||
| 1 week | +5.40% | ||
| Current month | +6.47% | ||
| 1 month | +6.69% | ||
| 3 months | +45.35% | ||
| 6 months | +96.62% | ||
| Current year | +98.74% |
| 1 week | 654 |  | 710 |
| 1 month | 647.3 | | 710 |
| Current year | 320.23 | | 772 |
| 1 year | 214.7 | | 772 |
| 3 years | 145 | | 772 |
| 5 years | 95.03 | | 772 |
| 10 years | 37.5 | | 772 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Chief Executive Officer | - | 18/10/2010 | |
Rafiq Raymond
DFI | Director of Finance/CFO | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
| Chairman | - | 17/10/2010 | |
| Director/Board Member | - | 17/10/2010 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.86% | +5.40% | +197.39% | +215.47% | 165M | |
| +0.20% | +1.94% | +10.74% | +85.91% | 46.74B | |
| +1.09% | +3.91% | +53.17% | +91.50% | 34.33B | |
| +2.59% | +0.23% | -7.64% | +38.69% | 11.57B | |
| -0.19% | -1.76% | +12.28% | +93.34% | 11.42B | |
| -0.57% | +0.96% | +37.43% | +127.27% | 9.09B | |
| +0.43% | -1.68% | +13.22% | +40.14% | 6.98B | |
| -0.61% | +2.05% | +30.63% | +250.61% | 6.62B | |
| +3.58% | +2.85% | +51.27% | -16.07% | 6.55B | |
| +0.73% | -2.94% | -35.25% | -1.81% | 5B | |
| Average | +0.62% | +0.42% | +36.32% | +92.51% | 13.85B | |
| Weighted average by Cap. | +0.66% | +0.90% | +23.16% | +84.40% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.66B 113M 98.94M 91.63M 85.78M 161M 10.71B 162M 1.09B 421M 5.27B 426M 417M 18.3B | 6.44B 129M 112M 104M 97.49M 183M 12.17B 184M 1.24B 479M 5.99B 484M 474M 20.8B |
| Net income | 157M 3.15M 2.74M 2.54M 2.38M 4.46M 297M 4.49M 30.14M 11.68M 146M 11.81M 11.56M 507M | 40.22M 806K 702K 651K 609K 1.14M 76.01M 1.15M 7.72M 2.99M 37.41M 3.02M 2.96M 130M |
| Net Debt | 2.6B 52.04M 45.38M 42.03M 39.34M 73.78M 4.91B 74.23M 499M 193M 2.42B 195M 191M 8.39B | 1.11B 22.24M 19.39M 17.96M 16.81M 31.53M 2.1B 31.72M 213M 82.56M 1.03B 83.47M 81.68M 3.59B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/26 | 694.00 £ | -0.86% | 3,866 |
| 17/06/26 | 700.01 £ | +5.40% | 9,096 |
| 16/06/26 | 664.14 £ | +0.30% | 2,709 |
| 15/06/26 | 662.15 £ | +0.56% | 1,433 |
- Stock Market
- Stocks
- MIPH Stock
Select your edition
All financial news and data tailored to specific country editions
